Trial · NCT03314935
Results by group119
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 119
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 | 8 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 | 6 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 | 13 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 50 mg + Gemcitabine + Cisplatin | 7 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 75 mg + Gemcitabine + Cisplatin | 4 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin | 46 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel | 7 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel | 5 | Participants | ||
| Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel | 51 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 50 mg + mFOLFOX6 | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 75 mg + mFOLFOX6 | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 100 mg + mFOLFOX6 | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin | 1 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 50 mg + Paclitaxel | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 75 mg + Paclitaxel | 0 | Participants | ||
| Phase 1: Number of Participants With Any Dose-limiting Toxicity (DLT) | Phase 1: INCB001158 100 mg + Paclitaxel | 0 | Participants | ||
| Recommended Phase 2 Dose (RP2D) of INCB001158 When Given in Combination With Each Chemotherapy Regimen | All Phase 1 Participants | 100 | milligrams | ||
| Phase 2: Objective Response Rate (ORR) | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | 0.0 | 95% Confidence Interval 0.0 to 36.9 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03314935/results